From: Cancer immunotherapies targeting the PD-1 signaling pathway
Target | Agent | Phase | Clinical effect | Reference |
---|---|---|---|---|
melanoma | pembrolizumab | 2 | 6MOS 34% (2 mg/kg) vs. 38% (10 mg/kg), vs 16% :docetaxel (n = 540) | [88] |
3 | 1 year-OS 74% (2wks) vs. 38% (3wks), vs 11% :docetaxel (n = 834) | [89] | ||
nivolumab | 3 | 1 year-OS 73% vs 42% (dacarbazine) (n = 418) | [89] | |
3 | ORR 32% vs. 11% (dacarbazine) (n = 405) | [90] | ||
non-small cell lung cancer | pembrolizumab | 1 | ORR 19.4%, mOS12.5 M (total), ORR 45.2% (n = 72, PD-L1+) (n = 495) | [91] |
nivolumab | 3 | mOS 9.2 M (vs 6.0 M:docetaxel) (n = 272) | [57] | |
3 | mOS12.2 M (vs 9.7 M:docetaxel (n = 582) | [92] | ||
durvalumab | 1/2 | ORR 14% (n = 149, total), 23% (PD-L1+) | [72] | |
atezolizumab | 2 | ORR 15% (n = 144, total), 38% (n = 24, PD-L1+) | [93] | |
small cell lung cancer | nivolumab | 1/2 | ORR 18% (n = 40, nivo), 17% (n = 46, combined with chemotherapy) | [94] |
pembrolizumab | 1 | ORR 25% (n = 16) | [95] | |
head and neck cancer | durvalumab | 1/2 | ORR 12% (n = 62) | [96] |
pembrolizumab | 1 | ORR 24.8% (n = 117) | [97] | |
renal cell cancer | nivolumab | 3 | ORR 25%, mOS 25.0 M, (vs. ORR 5%, mOS 19Ms in everolimus) (n = 821) | [98] |
bladder cancer | atezolizumab | 1 | ORR 26% (n = 310, total), 43% (PD-L1+) | [99] |
pembrolizumab | 1 | ORR 25% (n = 33, total), 38% (PD-L1+) | [100] | |
ovarian cancer | nivolumab | 2 | ORR 15% (n = 20, total), mOS 20.0 M ORR 20% (n = 10, 3 mg/kg) | [60] |
avelumab | 1 | ORR 10% (n = 124) | [101] | |
pembrolizumab | 1 | ORR 11.5% (PD-L1+) (n = 49) | [63] | |
uterine endometrial cancer | pembrolizumab | 1 | ORR 12.5% (PD-L1+) (n = 24) | [102] |
uterine cervical cancer | pembrolizumab | 1 | ORR 12.5% (PD-L1+) (n = 24) | [103] |
uterine sarcoma | nivolumab | 1 | ORR 0% (n = 12) | [104] |
gastric cancer | pembrolizumab | 1 | ORR 31% (n = 39) | [79] |
esophageal cancer | pembrolizumab | 1 | ORR 30% (PD-L1+) (n = 23) | [105] |
DNA mismatch repair deficient colon | pembrolizumab | 2 | ORR 40% (n = 10, MMRd colon), vs 0% (n = 18) in MMRw, vs71% (n = 7), MMR-non-colon [cholangiocarcinoma, endometrial cancer and pancreatic cancer].) | [73]. |
DNA mismatch repair deficient endometrial cancer | pembrolizumab | 2 | ir-ORR 67% (n = 9) | [106] |
hepatocellular carcinoma | nivolumab | 1/2 | ORR 9% (n = 91), 6 month-OS 69%. | [107] |
breast cancer | atezolizumab | 1 | ORR 12% (n = 27) | [108] |
pembrolizumab | 1 | ORR 19% (n = 25) (PD-L1+) | [109] | |
Merkel cell carcinoma | pembrolizumab | 2 | ORR 56% (n = 25), 6 M-PFS 67% | [110] |
thyroid cancer | pembrolizumab | 1 | ORR 9.1% (n = 22), mOS not reached, 1 year-OS 89.9%. | [111] |
Hodgikin lymphoma | nivolumab | 1 | ORR 87%, 24wks-PFS 86%(n = 23) | [112] |
pembrolizumab | 1 | ORR 64% (n = 31), 52wks-PFS 46%. | [113] | |
follicular lymphoma | nivolumab | 1 | ORR 40% (n = 10) | [114] |
diffuse large B-cell lymphoma | nivolumab | 1 | ORR 36% (n = 11) | [114] |
mycosisfungoides | nivolumab | 1 | ORR 15% (n = 13) | [114] |
peripheral T-cell lymphoma | nivolumab | 1 | ORR 40% (n = 5) | [114] |